dr. o’donnell on the importance of identifying molecular subsets in urothelial cancer
Published 5 years ago • 22 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
0:23
copy of dr. o’donnell on the importance of identifying molecular subsets in urothelial cancer
-
1:21
dr. o’donnell on pd-l1 testing in bladder cancer
-
2:07
dr. o’donnell on the evolution of immunotherapy in metastatic bladder cancer
-
1:09
dr. grivas on the future of molecular subtyping in urothelial cancer
-
0:54
dr. o’donnell on challenges with pd-l1 testing in bladder cancer
-
1:06
dr. o'donnell compares checkpoint inhibitors in bladder cancer
-
1:29
dr. bochner on the standardization of molecular profiling in bladder cancer
-
1:48
dr. bochner on molecular profiling in bladder cancer
-
1:00
dr. joshi on durvalumab and radiation therapy in locally advanced urothelial cancer of the bladder
-
1:03
dr. peter o’donnell on atezolizumab and imvigor 210
-
1:12
dr. o’donnell on ongoing immunotherapy trials in bladder cancer
-
1:55
dr. o'neil on standard of care in muscle-invasive bladder cancer
-
1:26
analyzing the role of molecular profiling in patients with bladder cancer
-
0:46
molecular markers guiding treatment approaches in bladder cancer
-
1:50
dr. powles on the current state of research in bladder cancer
-
8:26
the role of molecular markers in bladder cancer
-
36:31
novel anti-bladder cancer therapeutics
-
0:57
future use of liquid biopsies in bladder cancer diagnosis
-
1:17
recent advances in the treatment of upper tract urothelial carcinoma